Does DSIP actually improve sleep?

Yes, controlled human studies from the 1980s showed improved sleep quality in chronic insomniacs. The enhancement is specifically in slow-wave (delta) sleep, the deepest and most restorative sleep phase. These findings have not been replicated with modern clinical trial standards.

How does DSIP compare to melatonin for sleep?

They work through different mechanisms. Melatonin regulates sleep-wake timing through circadian clock signaling. DSIP enhances deep sleep quality through broad neuromodulation. Melatonin has decades more clinical evidence and is widely available as an OTC supplement. DSIP has older but real human data for deep sleep improvement.

Human studies from the 1970s and 1980s report generally favorable safety with minimal side effects. As an naturally occurring peptide with a short half-life (approximately 7-8 minutes), systemic exposure is limited. Long-term safety with repeated exogenous use is not characterized.

Why did DSIP research decline after the 1980s?

Sleep medicine developed more selective and commercially viable approaches. The short half-life of DSIP (7-8 minutes) presented practical challenges for therapeutic development. Academic interest shifted toward receptor-specific sleep medications and newer peptide targets.

Can DSIP help with stress?

DSIP modulates the HPA axis and reduces cortisol output, suggesting stress-buffering properties. This has been demonstrated in animal models and supported by limited human data. Whether this offers advantages over established stress-management approaches is not established.

Have any randomized controlled human trials been completed?

Controlled human studies demonstrated improved sleep quality in chronic insomniacs treated with DSIP. Schneider-Helmert (1985) is the most cited study. The findings are real but have not been replicated with modern trial methodology

What does the research show about: DSIP enhances slow-wave (delta) sleep specifically, the deepest and most restora?

DSIP enhances slow-wave (delta) sleep specifically, the deepest and most restorative sleep phase. This specificity for deep sleep distinguishes DSIP from sedative-hypnotics that may increase total sleep time without improving sleep architecture

What does the research show about: Analgesic properties documented in human chronic pain patients (Larbig et al., 1?

Analgesic properties documented in human chronic pain patients (Larbig et al., 1984). The pain-sleep connection is clinically relevant because chronic pain is one of the most common causes of sleep disruption

What mechanism of action has been identified?

The broad mechanism of action involves opioid, GABA, and HPA axis modulation simultaneously. This multi-system approach may explain the combined sleep and stress benefits but raises questions about specificity

What does the research show about: The short half-life of approximately 7-8 minutes suggests downstream signaling c?

The short half-life of approximately 7-8 minutes suggests downstream signaling cascades rather than sustained receptor occupancy. This pharmacokinetic profile is unusual and may limit practical therapeutic application

reviewed april 2026|next review october 2026|88 physicians psi has verified|518 published studies

DSIP

Delta sleep-inducing peptide (DSIP) is a naturally occurring (the body's own) nonapeptide first isolated from cerebral venous blood during induced slow-wave sleep in 1977, with controlled human data demonstrating improved sleep quality in chronic insomniacs.

Evidence landscape: 518 published studies

518 published items. 17 human studies and 165 animal studies. One of the most extensively studied sleep peptides, though the human data is predominantly from the 1980s.

17 Human
165 Animal
18 Reviews
318 Other research

DSIP is a naturally occurring peptide produced in the brain during deep sleep. First isolated from cerebral venous blood in 1977 during induced slow-wave sleep.

Controlled studies from the 1980s demonstrated improved sleep quality in chronic insomniacs, specifically enhancing delta (slow-wave) sleep - the deepest and most restorative sleep phase.

Acts simultaneously on opioid, GABA, and hypothalamic hormone (HPA axis) pathways rather than a single target. Broad mechanism is both the strength and the limitation.

PSI Assessment

First isolated from cerebral venous blood during induced slow-wave sleep in 1977, delta sleep-inducing peptide is one of the few research peptides with controlled human sleep data. Studies from the 1980s demonstrated improved sleep quality in chronic insomniacs, specifically enhancing the deepest and most restorative sleep phase (slow-wave delta sleep). The mechanism is broad rather than targeted, acting simultaneously on opioid, GABA, and hypothalamic hormone pathways. The human evidence is real but dated, and modern sleep research has not revisited DSIP with contemporary trial methodology.

Controlled human sleep data from the 1980s. One of the few research peptides with documented sleep efficacy in insomniacs. No modern trial replication.

The mechanism is multi-system neuromodulation rather than single-target receptor agonism. DSIP modulates delta-opioid receptor activity, enhances GABAergic tone, and influences the HPA (hypothalamic-pituitary-adrenal) axis. The peptide's short half-life (7-8 minutes) suggests it triggers downstream signaling cascades rather than maintaining sustained receptor occupancy. The sleep-promoting effect appears to involve restoration of normal sleep architecture rather than sedation.

What the evidence supports

DSIP enhances slow-wave sleep quality in controlled human studies, specifically in chronic insomniacs. The peptide is naturally occurring (the body's own) and was isolated from cerebral venous blood during induced slow-wave sleep. Multi-system neuromodulation (opioid, GABAergic, HPA axis) is documented across animal and human studies. The evidence base of 518 published studies is substantial for a sleep peptide.

What is not yet established

Whether the 1980s human sleep data would replicate with modern polysomnographic methodology and trial design. The optimal dosing and administration timing for sleep applications. Whether stress and pain modulation effects are clinically meaningful in humans. Long-term safety and dependence potential.

Research Evidence

The findings below cover the controlled human insomnia data, the multi-system mechanism, and the stress/cortisol modulation observed in animal models.

Evidence by condition

Evidence dimensions across DSIP's investigated conditions. Sleep has the deepest human evidence. Stress and pain modulation are primarily from animal models (preclinical).

Condition	Mechanism	Animal evidence	Human evidence	Replication
Sleep/Insomnia
Stress/Cortisol Modulation
Pain Modulation
Circadian Regulation

Controlled human studies from the 1980s demonstrated improved sleep quality in chronic insomniacs. Schneider-Helmert (1985) showed enhanced slow-wave sleep duration and sleep efficiency. Multiple European research groups published human sleep data throughout the 1980s.

The human sleep data is older but real. Study designs do not meet current clinical trial standards. Whether the findings would replicate with modern polysomnographic methodology is unknown.

DSIP acts simultaneously on opioid receptors (primarily delta-opioid), the GABAergic system (the primary inhibitory system promoting sleep), and the HPA axis (hypothalamic-pituitary-adrenal, modulating cortisol). This multi-system approach may explain combined sleep and stress benefits.

The broad mechanism is both the strength (multiple sleep-promoting effects) and the limitation (non-selective, raising questions about specificity compared to modern targeted sleep therapeutics).

Animal models consistently show DSIP modulates the HPA axis and reduces cortisol output. Limited human data supports cortisol modulation during sleep. Analgesic properties were documented in human chronic pain patients by Larbig and colleagues (1984).

The stress and pain modulation effects add clinical interest beyond sleep alone, though human data for these applications is more limited than for sleep.

17 Human|165 Animal|18 Reviews

View all 518 indexed studies

How DSIP Works

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a naturally occurring nonapeptide that enhances slow-wave sleep through multi-system neuromodulation of opioid, GABAergic, and HPA axis pathways.

DSIP works by enhancing the deepest phase of sleep, called delta or slow-wave sleep. This is the phase where your body does most of its physical repair and where growth hormone is released. DSIP appears to promote this deep sleep by acting on multiple brain systems at once: it interacts with pain-regulating pathways, the calming GABA system, and the hormones that control your sleep-wake cycle. It also helps regulate stress hormones, which is why researchers have studied it for both sleep and stress adaptation.

For a more detailed view of the biology, here is what researchers have observed at the molecular level.

DSIP modulates sleep architecture through interactions with delta-opioid receptors, GABAergic transmission, and hypothalamic releasing hormones. It inhibits somatostatin release, modulates ACTH/corticotropin secretion (reducing cortisol output), and normalizes disrupted circadian rhythms. The short half-life (7-8 minutes) suggests downstream signaling cascades rather than sustained receptor occupancy.

What is DSIP being studied for?

Researchers are studying DSIP across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for DSIP overall. This means a compound can have human studies for one condition but only animal data for another.

Sleep/Insomnia

·Human Trials

Controlled human studies from the 1980s demonstrated improved sleep quality in chronic insomniacs. DSIP enhanced slow-wave (delta) sleep duration and sleep efficiency.

Limitations: Study designs do not meet current clinical trial standards. No modern randomized controlled trial has been conducted. Whether DSIP offers advantages over current sleep medications is unknown.

Stress/Cortisol Modulation

·Animal Studies

DSIP modulates HPA axis activity and reduces cortisol output in animal and some human studies. The stress-adaptation effect is separate from but complementary to the sleep effects.

Limitations: Human data on stress modulation is limited. Most stress-response data comes from animal models (preclinical).

Pain Modulation

·Animal Studies

Analgesic properties documented in human studies of chronic pain patients (Larbig et al., 1984), likely mediated through delta-opioid receptor interaction.

Limitations: The human pain data is from the 1980s with small sample sizes. Modern pain research has not revisited DSIP.

Circadian Regulation

·Preclinical

Animal studies (preclinical) suggest DSIP can normalize disrupted circadian rhythms through hypothalamic hormone regulation.

Limitations: Primarily animal data. Melatonin has a vastly larger evidence base for circadian regulation.

Safety and Regulatory Status

FDA Status: Not FDA-approved for any indication.

Availability: Currently on the FDA Category 2 list, meaning licensed pharmacies cannot compound it. Expected to become available through licensed pharmacies following regulatory review per the February 2026 HHS announcement.

Safety context: DSIP is naturally occurring (the body's own) with a short half-life of approximately 7-8 minutes, limiting systemic exposure.

Human studies from the 1970s and 1980s report generally favorable safety with minimal side effects. The short half-life limits systemic exposure. As a naturally occurring peptide, DSIP has a baseline safety context.

Peptide Structure

Technical molecular data for researchers and clinicians.

Questions and Comparisons

Questions the evidence raises for a DSIP discussion.

Comparison and Related Research

DSIP is most often compared with Selank (anxiolytic, different mechanism), Pinealon (sleep via melatonin pathway), and GHRP-6 (GH secretagogue with sleep as secondary effect).

Head-to-head comparisons

Full research comparisons covering DSIP and another peptide side by side.

DSIP vs Selank

DSIP targets sleep architecture. Selank targets anxiety through GABA. Both used for relaxation but through different mechanisms. Evidence-graded comparison.

View full comparison

Related compounds

Selank Semax Pinealon Epitalon

Frequently Asked Questions

References

Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.

1.Clinical trial testing delta sleep-inducing peptide (DSIP) in patients with chronic insomnia. Treatment normalized several sleep parameters in middle-aged and elderly participants, with effects persisting after the treatment period ended.Schneider-Helmert D et al., 1986 in Eur Neurol. View on PubMed
2.The original isolation and characterization of DSIP from rabbit brain. This foundational study identified the nine-amino-acid peptide sequence and confirmed its ability to induce delta-wave sleep patterns in recipient animals, establishing a new field of sleep peptide research.Schoenenberger GA et al., 1977 in Proc Natl Acad Sci U S A. View on PubMed
3.Pilot clinical study testing DSIP in patients with chronic pain conditions. Treatment produced analgesic effects and improved sleep quality, suggesting that the peptide's pain-modulating properties may work through interactions with the body's endogenous opioid system.Larbig W et al., 1984 in Eur Neurol. View on PubMed
4.Comprehensive review covering the discovery, characterization, and biological activities of DSIP. Summarized evidence for sleep regulation, stress modulation, and pain modification, while noting the challenges of studying a peptide that degrades rapidly in blood.Graf MV, Kastin AJ, 1986 in Peptides. View on PubMed

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.